Hou Da-Yong, Li Xiang-Peng, Wang Yue-Ze, Zhang Peng, Wu Jiong-Cheng, You Hui-Hui, Lv Mei-Yu, Zhou Shi-An, Liu Xiao, Zhang Gao, An Hong-Wei, Wang Hao, Xu Wanhai
NHC Key Laboratory of Molecular Probe and Targeted Theranostics, Harbin Medical University, Harbin, 150001, China; Department of PET-CT/MRI, Harbin Medical University Cancer Hospital, Harbin, 150001, China; Faculty of Dentistry, The University of Hong Kong, 34 Hospital Road, Sai Ying Pun, 999077, Hong Kong, China.
NHC Key Laboratory of Molecular Probe and Targeted Theranostics, Harbin Medical University, Harbin, 150001, China; Department of PET-CT/MRI, Harbin Medical University Cancer Hospital, Harbin, 150001, China; CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology (NCNST), Beijing, 100190, China.
Biomaterials. 2026 Feb;325:123549. doi: 10.1016/j.biomaterials.2025.123549. Epub 2025 Jul 13.
Currently, surgical intervention remains the foundation in curing most solid tumors. Over the past few decades, even with rapid intraoperative tissue pathology assessment, the overall rate of positive surgical margins for tumors stagnated between 15 % and 60 %. The increased local recurrence rates and poor prognoses associated with various cancers, such as head and neck, brain, breast, lung, prostate, and gastrointestinal cancers, are linked to positive margins. Recently, driven by the concept of precise surgery, significant advancements have been reported in the intraoperative use of fluorescent contrast agents in the field of surgery. Molecular imaging via intraoperative fluorescence plays a guiding role in surgery, providing surgeons with visible fluorescent images. In clinical applications, fluorescent contrast agents can clearly delineate tumor boundaries, offering high recognition capacities and real-time guidance during surgery. Additionally, they can localize lymph node metastases, detect small metastatic lesions, and identify critical anatomical structures during surgery, thus reducing the risk of collateral damage. An ideal surgical guidance technology should lack radiation and display a high sensitivity and good resolution and an adjustable field of view, with rapid imaging. Enhancing the tissue penetration of fluorescence and targeting capacities of molecular probes are critical in providing more comprehensive tumor-related data. Additionally, screening and identifying other tumor biomarkers and more of their corresponding targeted molecular data are essential in enhancing the specificity of molecular imaging. Finally, the investigation and use of a wider range of near-infrared fluorescent dyes with improved biocompatibilities and imaging are critical in designing synthetic probes for application in intraoperative navigation. The development of novel, efficient, safe fluorescent contrast agents is a critical direction in current pharmaceutical research and development.
目前,手术干预仍然是治愈大多数实体瘤的基础。在过去几十年里,即使术中组织病理学评估迅速发展,肿瘤手术切缘阳性的总体发生率仍停滞在15%至60%之间。与各种癌症(如头颈癌、脑癌、乳腺癌、肺癌、前列腺癌和胃肠道癌)相关的局部复发率增加和预后不良与切缘阳性有关。最近,在精准手术概念的推动下,手术领域术中使用荧光造影剂有了显著进展。术中荧光分子成像在手术中起指导作用,为外科医生提供可见的荧光图像。在临床应用中,荧光造影剂可以清晰地勾勒肿瘤边界,在手术中具有高识别能力和实时引导作用。此外,它们可以定位淋巴结转移,检测小的转移病灶,并在手术中识别关键解剖结构,从而降低附带损伤的风险。理想的手术引导技术应无辐射,具有高灵敏度、良好分辨率、可调节视野且成像迅速。增强荧光的组织穿透能力和分子探针的靶向能力对于提供更全面的肿瘤相关数据至关重要。此外,筛选和识别其他肿瘤生物标志物及其更多相应的靶向分子数据对于提高分子成像的特异性至关重要。最后,研究和使用具有更好生物相容性和成像效果的更广泛的近红外荧光染料对于设计用于术中导航的合成探针至关重要。开发新型、高效、安全的荧光造影剂是当前药物研发的一个关键方向。